AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Mannkind Soars 38.13% on Strategic Acquisition of scPharmaceuticals
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Sep 2, 2025 9:36 am ET1min read
Aime SummaryMannkind's stock surged by 38.13% in pre-market trading on September 2, 2025, driven by significant developments in the company's strategic acquisitions and market outlook.
Mannkind Corporation has entered into a definitive agreement to acquire
for approximately $290 million. This acquisition is expected to accelerate Mannkind's revenue growth and expand its cardiometabolic business. The deal has been met with positive reactions from analysts, with H.C. Wainwright reiterating a Buy rating on and setting a price target of $9, citing the acquisition as a strategic move that aligns with the company's growth objectives.Leerink Partners has also reiterated a Buy rating on Mannkind, maintaining a price target of $7. The consensus rating for Mannkind remains positive, with a score of 3.29 based on five buy ratings and no hold or sell ratings. This strong analyst support reflects the market's confidence in Mannkind's strategic direction and growth potential.
Mannkind's acquisition of
is seen as a significant step in expanding its product portfolio and enhancing its market position. The deal includes a cash payment of $5.35 per share plus a contingent value right, representing a 31% premium to the previous trading price. This acquisition is expected to drive Mannkind's growth in the cardiometabolic space, leveraging scPharmaceuticals' innovative technologies and products.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Dakota Gold DC shares plummeted 6.90% as mining stocks selloff follows sharp gold silver price declines
Dec.30 2025
Integra Resources shares plunge 9.58% on Dec. 30 2025 as project delays regulatory uncertainties spook investors
Dec.30 2025
AXT shares fell 5.07% in pre-market trading on Dec. 30 2025 amid sector pressures and speculative positioning adjustments.
Dec.30 2025
Autozi Internet shares surged 8.76% on strategic AI pivot and regulatory progress
Dec.30 2025
ProKidney shares plunged 13.04% due to regulatory scrutiny and operational concerns
Dec.30 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet